Follow-up evaluation of clinical markers and inflammatory, biochemical and hormonal profiles in children with bodyweight problems

Ioana Țaranu1, Victoria Creț2, Sorana D. Bolboacă1
1 Department of Medical Informatics and Biostatistics, Faculty of Medicine, “Iuliu Hățieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
2 Emergency Regional Children Hospital, First pediatric Clinic, Cluj-Napoca, Romania

1 Introduction

The morbidity in obese patients is alarmingly elevated (1). The activation of inflammatory pathways, hormonal abnormalities (i.e., the onset of insulin-resistance (IR) and hypothalamic-pituitary-adrenal axis dysregulation) in obesity are well evidenced (2,3). Expert recommendations upon laboratory testing and screening of comorbidities in pediatric obesity have not reached a consensus (4). A longitudinal approach might be more useful than cross-sectional studies to describe changes in clinical and blood parameters.

Aim: to evaluate the relationship between changes in clinical parameters and the inflammatory, biochemical and hormonal profiles of obese and overweight children over a 4 to 12-month period.

2 Method

• observational retrospective study on obese and overweight children evaluated from January 2017 to March 2019 in the First Pediatric Clinic from Cluj-Napoca, Romania;
• minimum follow-up period: 4 months;
• clinical examination data and blood analysis: inflammatory, biochemical and hormonal (Fig.1).

3 Results

✓ 22 children aged 2 years - 17 years (17 girls and 5 boys):
✓ baseline: 20 obese (≥ 95th WHO percentile) and 2 overweight (≥85th WHO percentile) follow-up: 16 obese and 4 overweight;
✓ a trend of decreasing the percentile, but without reaching statistical significance (P-value=0.459, Fig. 2);
✓ blood insulin level increased: baseline mean was 17.6 ± 9.8 µU/ml and follow-up mean was 25.1 ± 17.1 µU/ml (P-value=0.050, Fig. 3);
✓ bodyweight and insulin levels were positively correlated at baseline (ρ=0.60, P-value=0.051, n=11) and at follow-up (ρ=0.53, P-value=0.028, n=17);
✓ one patient had hyperinsulinemia at the baseline evaluation and 5 patients developed it at follow-up;
✓ blood glucose level significantly reduced: baseline mean = 84.1 ±6.1 mg/dl and follow-up mean = 79.0 ±7.0 mg/dl (P-value=0.010, Fig. 4);
✓ neither the change in blood glucose, nor in the insulinemia or HOMA-ir value were correlated to changes in BMI or BMI-for-age percentiles (P-values > 0.05).

4 Conclusions

Changes in glucose homeostasis occur independently of bodyweight modifications during the early stage of obesity. Euglycemic hyperinsulinemia may reflect the mechanisms leading to insulin resistance, which plays a key role in obesity-associated comorbidities. Future prospective clinical and fundamental studies could bring a more detailed insight into these early subclinical changes.

References:

Acknowledgments: This work was supported by the Iuliu Hâțieganu University of Medicine and Pharmacy, Cluj-Napoca (PCD 1529/50/18.01.19).